In a dose-ranging program, what is the primary objective?

In a dose-ranging program, what is the primary objective?

• A. Identify a dose with the lowest cost.
• B. Incorporate biomarkers into endpoints.
• C. Identify a dose range where safety and efficacy are demonstrated with an acceptable risk-benefit.
• D. Focus only on pharmacodynamics.

Answer: (C)

In a dose-ranging program, the aim is to map how different doses affect both efficacy and safety so you can identify a dose range that provides therapeutic benefit without unacceptable risk. By testing multiple doses, you observe the exposure–response relationship, detect where increasing dose stops adding meaningful efficacy, and spot where adverse effects become unacceptable. This helps establish a therapeutic window and informs selecting the dose (or range) for later pivotal trials with an acceptable risk–benefit balance. It’s not primarily about cost, nor about biomarkers as endpoints, and while pharmacodynamics is part of the picture, the primary objective is a balanced demonstration of safety and efficacy across doses.

In a dose-ranging program, the aim is to map how different doses affect both efficacy and safety so you can identify a dose range that provides therapeutic benefit without unacceptable risk. By testing multiple doses, you observe the exposure–response relationship, detect where increasing dose stops adding meaningful efficacy, and spot where adverse effects become unacceptable. This helps establish a therapeutic window and informs selecting the dose (or range) for later pivotal trials with an acceptable risk–benefit balance. It’s not primarily about cost, nor about biomarkers as endpoints, and while pharmacodynamics is part of the picture, the primary objective is a balanced demonstration of safety and efficacy across doses.